🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 18 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/03/1994 | 8,38 | 8,75 | 8,38 | 8,44 | -0,74% | 4,48% | 191.600 |
| 04/03/1994 | 8,56 | 8,75 | 8,38 | 8,50 | +0,00% | 4,38% | 98.000 |
| 03/03/1994 | 8,50 | 8,75 | 8,50 | 8,50 | -0,73% | 2,94% | 181.800 |
| 02/03/1994 | 8,50 | 8,75 | 8,50 | 8,56 | -0,72% | 2,94% | 30.400 |
| 01/03/1994 | 8,75 | 8,75 | 8,50 | 8,63 | +1,47% | 2,86% | 237.600 |
| 28/02/1994 | 8,38 | 8,75 | 8,38 | 8,50 | +1,49% | 4,48% | 123.000 |
| 25/02/1994 | 8,88 | 9,00 | 8,25 | 8,38 | -6,94% | 8,45% | 1.175.400 |
| 24/02/1994 | 8,88 | 9,13 | 8,88 | 9,00 | -0,69% | 2,82% | 179.000 |
| 23/02/1994 | 9,13 | 9,13 | 8,88 | 9,06 | +0,69% | 2,74% | 58.600 |
| 22/02/1994 | 8,88 | 9,13 | 8,88 | 9,00 | +1,41% | 2,82% | 44.600 |
| 18/02/1994 | 8,88 | 9,13 | 8,88 | 8,88 | -1,39% | 2,82% | 69.400 |
| 17/02/1994 | 9,13 | 9,13 | 8,88 | 9,00 | +0,00% | 2,74% | 68.000 |
| 16/02/1994 | 8,88 | 9,13 | 8,88 | 9,00 | +1,41% | 2,82% | 24.200 |
| 15/02/1994 | 9,13 | 9,13 | 8,88 | 8,88 | -2,74% | 2,74% | 59.000 |
| 14/02/1994 | 9,13 | 9,13 | 8,88 | 9,13 | +0,69% | 2,74% | 80.800 |
| 11/02/1994 | 8,88 | 9,13 | 8,88 | 9,06 | -0,68% | 2,82% | 40.200 |
| 10/02/1994 | 9,38 | 9,38 | 8,88 | 9,13 | +0,00% | 5,33% | 399.600 |
| 09/02/1994 | 9,38 | 9,38 | 9,00 | 9,13 | -1,35% | 4,00% | 52.000 |
| 08/02/1994 | 9,13 | 9,38 | 9,13 | 9,25 | +1,37% | 2,74% | 100.000 |
| 07/02/1994 | 9,13 | 9,38 | 9,00 | 9,13 | +0,00% | 4,11% | 210.600 |
| 04/02/1994 | 9,50 | 9,50 | 9,13 | 9,13 | -2,01% | 3,95% | 27.600 |
| 03/02/1994 | 9,25 | 9,50 | 9,25 | 9,31 | -1,97% | 2,70% | 33.200 |
| 02/02/1994 | 9,38 | 9,63 | 9,25 | 9,50 | -0,65% | 4,00% | 468.000 |
| 01/02/1994 | 9,50 | 9,63 | 9,25 | 9,56 | +0,66% | 3,95% | 213.400 |
| 31/01/1994 | 9,25 | 9,63 | 9,00 | 9,50 | +3,40% | 6,76% | 202.000 |
| 28/01/1994 | 9,25 | 9,25 | 9,00 | 9,19 | +2,08% | 2,70% | 94.000 |
| 27/01/1994 | 8,94 | 9,25 | 8,94 | 9,00 | +0,00% | 3,50% | 162.000 |
| 26/01/1994 | 9,00 | 9,13 | 8,94 | 9,00 | +0,00% | 2,08% | 545.400 |
| 25/01/1994 | 9,25 | 9,38 | 9,00 | 9,00 | -5,26% | 4,05% | 2.765.400 |
| 24/01/1994 | 9,31 | 9,50 | 9,13 | 9,50 | +2,70% | 4,03% | 302.000 |